FDA seeks public input to support ibogaine research
The FDA issued a request for information (RFI) to gather comments on early-phase clinical trial design for ibogaine drug products, including dose selection, safety monitoring and ethical oversight. Stakeholders have 45 days to submit comments, with the deadline on Friday, November 20, 2026.
Primary source
FDA press announcement, October 5, 2026
FDA Seeks Public Input to Support Ibogaine Research
Read the source: FDA Seeks Public Input to Support Ibogaine Research fda.gov
Machine-summarized from the source above; not independently reported. How we use automation